<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4184130</article-id><article-id pub-id-type="publisher-id">1546-0096-12-S1-O12</article-id><article-id pub-id-type="doi">10.1186/1546-0096-12-S1-O12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Ruperto</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Brunner</surname><given-names>HI</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Kone-Paut</surname><given-names>I</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Magnusson</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Ozen</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Sztajnbok</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Anton</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Barash</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Corona</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Lheritier</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Gaillez</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Martini</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Lovell</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>PRINTO-Istituto Gaslini, Genova, Italy</aff><aff id="I2"><label>2</label>PRCSG, Cincinnati, USA</aff><aff id="I3"><label>3</label>Novartis Pharma AG, Basel, Switzerland</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>17</day><month>9</month><year>2014</year></pub-date><volume>12</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the 21st European Pediatric Rheumatology (PReS) Congress</named-content><named-content content-type="supplement-sponsor">The publication charges for this supplement were funded by the PReS 2014 congress.</named-content></supplement><fpage>O12</fpage><lpage>O12</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Ruperto et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Ruperto et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.ped-rheum.com/content/12/S1/O12"/><conference><conf-date>17-21 September 2014</conf-date><conf-name>21st European Pediatric Rheumatology (PReS) Congress</conf-name><conf-loc>Belgrade, Serbia</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Canakinumab (CAN), a selective, human, anti- interleukin-1&#x003b2; monoclonal antibody, has been shown to be efficacious in the treatment of SJIA (Ruperto et al. N Engl J Med 2012).</p></sec><sec><title>Objectives</title><p>To explore baseline demographics and clinical characteristics that are most predictive of response to CAN in CAN-na&#x000ef;ve SJIA patients during the initial 12 weeks of therapy.</p></sec><sec sec-type="methods"><title>Methods</title><p>Data from 3 trials were pooled for this analysis. CAN-na&#x000ef;ve patients (pts; n=178) aged 2&#x02013;19 years with active SJIA were enrolled and received sc CAN 4 mg/kg/month; Predictors of response (according to aACR* 30, 70, and Inactive Disease [ID]) at Days (D) 15, 29, 57 and 85 were explored using univariate and multivariate logistic regression analyses. The candidate predictors (categorical variables) of CAN-response considered were: Age group, Gender, Prior NSAIDS (no/yes), Prior MTX(no/yes), Steroids (0, &#x0003e;0 &#x02013; &#x02264;0.4;&#x0003e; 0.4), Number of Active Joints(&#x02264;10, 11-&#x02264;20, &#x0003e;20) and Joints with Limitation of Motion (&#x02264;10, 11-&#x02264;20,&#x0003e;20), CRP (elevated/normal) at baseline and at D15. All candidate predictors with p&#x0003c;0.1 in univariate analyses were included in the multivariate analysis. *ACR response plus absence of fever.</p></sec><sec sec-type="results"><title>Results</title><p>By week 2 there was substantial clinical benefit with 102 pts (57%) and 36 pts (20%) achieving aACR70 and ID, respectively; by week 12, 108 pts (61%) had aACR70 and 50 pts (28%) ID. The multivariate analysis indicated that normal CRP at D15 is the only predictor significant (all p &#x0003c; 0.05) for ID at all time-points (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table</label><caption><p>Inactive Disease - Multivariate logistic regression analysis on 12-week data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center">Variable*, Odds Ratio (95% CI)</th><th align="center">Day 15</th><th align="center">Day 29</th><th align="center">Day 57</th><th align="center">Day 85</th></tr></thead><tbody><tr><td align="center"><bold>CRP at Day 15 (elevated vs normal)</bold></td><td align="center"><bold>0.20 (0.07, 0.55)</bold></td><td align="center"><bold>0.14 (0.04, 0.41)</bold></td><td align="center"><bold>0.26 (0.10, 0.66)</bold></td><td align="center"><bold>0.31 (0.12, 0.82)</bold></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="center"><bold>Number of active joints (11-&#x02264;20 vs. &#x02264;10)</bold></td><td align="center">0.22 (0.03, 1.66)</td><td align="center">0.55 (0.09, 3.41)</td><td align="center"><bold>0.17 (0.031, 0.97)</bold></td><td align="center">0.37 (0.06, 2.10)</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="center"><bold>Number of active joints (&#x02264;10 vs. &#x0003e;20)</bold></td><td align="center">2.56 (0.12, 55.39)</td><td align="center">1.53 (0.06, 37.44)</td><td align="center"><bold>16.10 (1.00, 258.12)</bold></td><td align="center"><bold>25.41 (1.60, 404.61)</bold></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="center"><bold>Prior NSAID treatment (no vs. yes)</bold></td><td align="center">2.01 (0.71, 5.71)</td><td align="center"><bold>9.33 (2.44, 35.68)</bold></td><td align="center"><bold>3.10 (1.03, 9.31)</bold></td><td align="center"><bold>5.31 (1.66, 17.05)</bold></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="center"><bold>Steroid Level (0 vs. &#x0003e;0.4 mg/kg/day)</bold></td><td align="center">5.48 (0.97, 31.01)</td><td align="center"><bold>8.89 (1.26, 62.64)</bold></td><td align="center">2.98 (0.51, 17.46)</td><td align="center"><bold>11.16 (1.72, 72.34)</bold></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="center"><bold>Steroid Level (&#x0003e;0.4 vs. &#x0003e;0-&#x02264;0.4 mg/kg/day)</bold></td><td align="center">0.32 (0.08, 1.29)</td><td align="center">0.41 (0.09, 1.82)</td><td align="center">0.81 (0.25, 2.60)</td><td align="center"><bold>0.13 (0.03, 0.57)</bold></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="center"><bold>Prior MTX treatment (no vs. yes)</bold></td><td align="center">1.94 (0.75, 5.00)</td><td align="center">2.78 (0.93, 8.33)</td><td align="center"><bold>2.79 (1.04, 7.51)</bold></td><td align="center">1.77 (0.65, 4.83)</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="center"><bold>Prior anti-TNFs treatment (no vs. yes)</bold></td><td align="center">1.83 (0.52, 6.49)</td><td align="center">3.62 (0.77, 17.00)</td><td align="center">2.01 (0.63, 6.38)</td><td align="center"><bold>3.64 (1.04, 12.77)</bold></td></tr></tbody></table><table-wrap-foot><p>Values in bold are significant; *Significant in at least one time point</p></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions"><title>Conclusion</title><p>This exploratory analysis suggests that CAN-na&#x000ef;ve patients with normal CRP (i.e. &#x02264;10 mg/l) at Day 15, lower baseline steroid doses, low number of active joints, no prior anti-TNF or prior NSAID use are those most likely to achieve inactive disease up to 12 weeks.</p></sec><sec><title>Disclosure of interest</title><p>N. Ruperto Grant / Research Support from: To Gaslini Hospital: Abbott, Astrazeneca, BMS, Centocor Research &#x00026; Development, Eli Lilly and Company, "Francesco Angelini", Glaxo Smith &#x00026; Kline, Italfarmaco, Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences GmbH, Xoma, Wyeth Pharmaceuticals Inc., Speaker Bureau of: Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Roche, Wyeth, Pfizer, H. Brunner Consultant for: Novartis, Genentech, Pfizer, UCB, AstraZeneca, Biogen, Boehringer-Ingelheim, Regeneron, Paid Instructor for: Novartis, Speaker Bureau of: Novartis, Genentech, I. Kone-Paut Grant / Research Support from: SOBI, Chugai, Consultant for: Pfizer, SOBI, Novartis, AbbVie, Cellgene, Chugai, B. Magnusson: None declared., S. Ozen Consultant for: Novartis (Turkey), Speaker Bureau of: Speaker&#x02019;s fee from SOBI, F. Sztajnbok Grant / Research Support from: Institutional grant (UERJ) for participating in the canakinumab trial., Speaker Bureau of: Novartis-Brasil, J. Anton Consultant for: Novartis, Speaker Bureau of: Novartis, J. Barash Grant / Research Support from: Investigator in the Canakinumab study sponsored by Novartis, F. Corona: None declared., K. Lheritier Shareholder of: Novartis, Employee of: Novartis Pharma AG, C. Gaillez Employee of: Novartis Pharma AG, A. Martini Grant / Research Support from: Bristol Myers and Squibb, Centocor Research &#x00026; Development,Glaxo Smith &#x00026; Kline, Novartis, Pfizer Inc, Roche, Sanofi Aventis, Schwarz Biosciences GmbH, I declare that the Gaslini Hospital which is the public Hospital where I work as full time employee has received contributions to support the PRINTO research activities from the industries above mentioned. OLD: Francesco Angelini S.P.A., Janssen Biotech Inc, Abbott. , Consultant for: Bristol Myers and Squibb, Centocor Research &#x00026; Development, Glaxo Smith &#x00026; Kline, Novartis, Pfizer Inc, Roche, Sanofi Aventis, Schwarz Biosciences GmbH, I declare that the Gaslini Hospital which is the public Hospital where I work as full time employee has received contributions to support the PRINTO research activities from the industries above mentioned. , Speaker Bureau of: Abbott, Bristol Myers Squibb, Astellas, Boehringer, Italfarmaco, MedImmune, Novartis, NovoNordisk, Pfizer, Sanofi, Roche, Servier, D. Lovell Grant / Research Support from: National Institutes of Health- NIAMS , Consultant for: Astra-Zeneca, Centocor, Amgen, Bristol Meyers Squibb, Abbott, Pfizer, Regeneron, Roche, Novartis, UBC, Forest Research Institute, Horizon, Johnson &#x00026; Johnson, Speaker Bureau of: Novartis, Roche.</p></sec></body></article>